PathoQuest
Biologics & Biosimilars · Genomics & Genetic Testing
$4.1Mlatest round · Series B · Jul 2013 · 13 yr ago
1backers · Kurma Partners
50+team · employees, estimated range
20stories in the press
Overview
PathoQuest provides biosafety assays based on next-generation sequencing (NGS) for biologics quality testing. GMP biotesting for biopharmaceuticals. Learn more.
Key facts
These are the key facts about PathoQuest on Alion as of Nov 13, 2026. The latest round is Series B of $4.1M, announced in 2013.
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $4.1MSum of 1 equity round Alion knows
- Latest round
- Series B · $4.1M · Jul 11, 2013Press report · technologynetworks.com
Funding and backers
Total raised
$4.1M
1 round on record
Latest round
$4.1M
Series B · Jul 2013 · 13 yr ago
Team
51-200
employees, estimated range
Backers
1
Kurma Partners
The money's age
Long since its last round
160 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 11, 2013
Raised a round Series B $4.1M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Jul 2013 | $4.1M | — | technologynetworks.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Learn howCanal's TrueLink® NGS technology safeguards your template without the need for end repair.
ゲノム （ DNA ）、エピゲノム、トランスクリプトーム （ RNA ）を独自の技術で解析し、研究開発の効率・精度を格段に向上させます。次世代シーケンス（ NGS ）／ エピジェネティクス 研究の 実験デザイン から 情報 解析、論文化、事業化までオーダーメイドで支援します。.
Learn more about TwinStrands Biosciences Duplex Sequencing®, ultra-sensitive, accurate, and error-corrected sequencing technology.
IconPCR with AutoNorm gives you normalized, sequencing-ready NGS libraries in one step, with real-time per-well control for 16S…
SWAN Genomics is developing a plasmonic nanoantenna-based single-molecule DNA sequencing platform. Sequencing With A Nanoantenna.
Reduce expert workload per NGS case by up to 85%. Qnomx leverages AI to streamline NGS interpretation and generate clinician-ready reports.
Financials
Total raised
$4.1M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2013 | $4.1M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Kurma PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
MSK and PathoQuest Test Method to Detect Infection in Patients With Febrile Neutropenia AJMC
A new collaboration between PathoQuest and Memorial Sloan Kettering Cancer Center (MSK) will test the best method to identify microorganisms responsible for infections in patients with febrile neutropenia.
Read more
Report
PathoQuest Achieves GMP Certification for Quality Control Testing Services Pharmaceutical Technology
PathoQuest is the first French contract research organization (CRO) capable of offering GMP grade NGS-based testing services for quality control of biological drugs.
Read more
Report
Charles River and PathoQuest Publish Study Validating Proprietary Next-Generation Sequencing Viral Safety Assay Pharmaceutical Technology
The results showed that PathoQuest's proprietary NGS approach is an effective, more robust replacement to in vivo adventitious virus testing of cell substrates used in the production of biologics, like monoclonal antibodies, vaccines, cell, and gene thera
Read more
Report
Webinar - OCTOBER 6th, 2026 Leveraging Next-Generation Sequencing (NGS) for Adventitious Agent Testing: Pacira's Quality Control Strategy and Lessons Learned
Leveraging Next-Generation Sequencing (NGS) for Adventitious Agent Testing OCTOBER 6, 2026 11:00 EST 08:00 PST 17:00 CEST Duration: 30 minutes
Read more
Report
NEXT-GEN BIOSAFETY MASTERCLASS I SEPTEMBER 10, 2026 in Paris (France) I Agenda
Next-Gen Biosafety Masterclass Next Generation Sequencing (NGS) in Biosafety Testing: From Regulation to Routine Use SEPTEMBER 10, 2026 in Paris (France) Pathoquest is pleased to announce the upcoming Next-Gen Biosafety Masterclass: "Next Generation Seque
Read more
Report
Webinar - JUNE 18th, 2026 NGS in Viral Safety: What Do Regulators Really Expect?
NGS in Viral Safety What Do Regulators Really Expect? June 18, 2026 11:00 EST 08:00 PST 17:00 CEST Duration: 30 minutes The adoption of Next-Generation Sequencing (NGS) for viral safety testing is accelerating, raising a key question: what do regulators e
Read more
Report
Webinar - APR 21, 2026 Have we finally reached the end of in vitro testing? Positioning NGS in cell and gene therapy biosafety testing
Webinar Have we finally reached the end of in vitro testing? Positioning NGS in cell and gene therapy biosafety testing April 21, 2026 08:00 PDT 11:00 EDT 16:00 BST 17:00 CEST Online Webinar Join our upcoming webinar to explore how transcriptome-based Nex
Read more
Report
NEXT-GEN BIOSAFETY MASTERCLASS I SEPTEMBER 10, 2026 in Paris (France)
Next-Gen Biosafety Masterclass Next Generation Sequencing (NGS) in Biosafety Testing: From Regulation to Routine Use SEPTEMBER 10, 2026 in Paris (France) PathoQuest is pleased to announce the upcoming Next-Gen Biosafety Masterclass: "Next Generation Seque
Read more
Report
PRESS RELEASE: PathoQuest to Join Charles River Laboratories, Accelerating the Future of NGS-Based GMP Biosafety Testing Worldwide
PathoQuest, a pioneer and global leader in Next Generation Sequencing (NGS)-based biosafety testing, today announced that it has entered into a definitive agreement to be acquired by Charles River Laboratories, a leading global provider of products and se
Read more
Report
PathoQuest CEO Jean-François Brepson, Featured on Molecule to Market Podcast
PathoQuest CEO Jean-François Brepson, Featured on Molecule to Market Podcast. NOV 26, 2025 From Pharma to CRO entrepreneur. Jean-François Brepson, CEO of PathoQuest, joined the Molecule to Market podcast for a conversation about his journey from global ph
Read more
Report
Show more news
How to cite this page
Alion, "PathoQuest: key facts", as of Nov 13, 2026. https://alion.io/company/pathoquest-2
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0